Tacrolimus‐associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation
Open Access
- 5 February 2013
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 88 (4) , 301-305
Abstract
Tacrolimus‐associated posterior reversible encephalopathy syndrome (PRES) is a potential complication of allogeneic stem cell transplant (SCT). Due to the paucity of information on the management of PRES in SCT patients receiving tacrolimus, more information is needed on trends associated with the incidence of PRES and to characterize its management. A retrospective review was conducted of patients receiving tacrolimus for prevention of graft versus host disease (GVHD) after allogeneic SCT who developed PRES from September 2008 to July 2011. Nineteen patients were identified. Altered mental status, seizures, and visual abnormalities were experienced by 78.9%, 52.6%, and 31.5% of the patients, respectively, at time of PRES onset. Compared with baseline, patients with PRES were likely to have an increase in mean arterial pressure (P < 0.0001) and serum creatinine. Elevated tacrolimus levels and hypomagnesemia were not observed with PRES onset. Tacrolimus was managed in three general strategy groups: not held, held then continued, and switched to another agent. Survival was defined as survival to discharge from PRES hospitalization. When tacrolimus was not held, held then continued, or switched to another agent, 40% (2 of 5), 40% (4/10), and 50% (2/4) survived to discharge, respectively. PRES was associated with high blood pressure and adequate blood pressure control should be part of its management. No management strategy pertaining to tacrolimus usage appeared more beneficial over another. Am. J. Hematol. 88:301–305, 2013.Keywords
This publication has 14 references indexed in Scilit:
- Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an updateCurrent Opinion in Hematology, 2010
- Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor‐related neurotoxicity after hematopoietic stem cell transplantationClinical Transplantation, 2010
- Tacrolimus-Associated Posterior Reversible Encephalopathy Syndrome after Solid Organ TransplantationEuropean Neurology, 2010
- Calcineurin Inhibitor NephrotoxicityClinical Journal of the American Society of Nephrology, 2009
- Posterior reversible encephalopathy syndrome due to sirolimusBone Marrow Transplantation, 2007
- Reversible posterior leukoencephalopathy syndrome: a misnomer reviewedInternal Medicine Journal, 2005
- Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignanciesAmerican Journal of Hematology, 2004
- FK506-induced intractable leukoencephalopathy following allogeneic bone marrow transplantationBone Marrow Transplantation, 2000
- Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantationBone Marrow Transplantation, 1999
- A Reversible Posterior Leukoencephalopathy SyndromeNew England Journal of Medicine, 1996